OVID Stock Analysis: Buy, Sell, or Hold?
OVID - Ovid Therapeutics Inc. Common Stock
$2.80
0.06 (2.19%)
▲
5d:
-1.06%
30d:
+16.67%
90d:
+14.75%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When OVID Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: OVID shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: OVID shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: OVID is currently trading at $2.80, which is considered extended relative to its 30-day fair value range of $2.34 to $2.73.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $2.43, while resistance sits at $2.95.
Market Sentiment: OVID scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.69 (+103.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $2.43, while resistance sits at $2.95.
Market Sentiment: OVID scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.69 (+103.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.34 -
$2.73
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 103.3% below Wall St target ($5.69)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.34 -
$2.73
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.43
Resistance Level
$2.95
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.10
Wall Street Target
$5.69
(+103.3%)
Revenue Growth (YoY)
-88.3%
Share & Embed Analysis
Last updated: August 23, 2026 7:49 AM ET
Data refreshes hourly during market hours. Next update: 8:49 AM
Data refreshes hourly during market hours. Next update: 8:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OVID showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1100 | 43 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
